By Karen Roman
Agendia, Inc. said its gene expression profiling test MammaPrint can predict extended endocrine therapy benefit for patients with early-stage breast cancer.
The test helps optimizing additional therapy and can potentially improve survival, the company said.
“These findings provide clinicians with a powerful tool to optimize endocrine treatment duration, potentially sparing MP High-Risk patients from unnecessary extended therapy while ensuring MP Low-Risk patients receive the full protective benefits they need,” said Laura van ‘t Veer, Agendia’s Chief Research Officer and co-founder.
Contact:
